HUP9900006A3 - Cyclic gmp-specific phosphodiesterase inhibitors, their production and medicament containing them - Google Patents

Cyclic gmp-specific phosphodiesterase inhibitors, their production and medicament containing them

Info

Publication number
HUP9900006A3
HUP9900006A3 HU9900006A HUP9900006A HUP9900006A3 HU P9900006 A3 HUP9900006 A3 HU P9900006A3 HU 9900006 A HU9900006 A HU 9900006A HU P9900006 A HUP9900006 A HU P9900006A HU P9900006 A3 HUP9900006 A3 HU P9900006A3
Authority
HU
Hungary
Prior art keywords
production
phosphodiesterase inhibitors
medicament containing
cyclic gmp
specific phosphodiesterase
Prior art date
Application number
HU9900006A
Other languages
English (en)
Original Assignee
Icos Corp Bothell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp Bothell filed Critical Icos Corp Bothell
Publication of HUP9900006A2 publication Critical patent/HUP9900006A2/hu
Publication of HUP9900006A3 publication Critical patent/HUP9900006A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HU9900006A 1995-07-14 1996-07-11 Cyclic gmp-specific phosphodiesterase inhibitors, their production and medicament containing them HUP9900006A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9514465.5A GB9514465D0 (en) 1995-07-14 1995-07-14 Chemical compounds

Publications (2)

Publication Number Publication Date
HUP9900006A2 HUP9900006A2 (hu) 1999-04-28
HUP9900006A3 true HUP9900006A3 (en) 1999-11-29

Family

ID=10777696

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900006A HUP9900006A3 (en) 1995-07-14 1996-07-11 Cyclic gmp-specific phosphodiesterase inhibitors, their production and medicament containing them

Country Status (24)

Country Link
US (1) US5981527A (hu)
EP (1) EP0846118B1 (hu)
JP (1) JP4150818B2 (hu)
CN (1) CN1069318C (hu)
AR (1) AR003455A1 (hu)
AT (1) ATE216997T1 (hu)
AU (1) AU702324B2 (hu)
BR (1) BR9609780A (hu)
CA (1) CA2226761A1 (hu)
CO (1) CO4700455A1 (hu)
CZ (1) CZ3298A3 (hu)
DE (1) DE69621026T2 (hu)
ES (1) ES2176471T3 (hu)
GB (1) GB9514465D0 (hu)
HR (1) HRP960321B1 (hu)
HU (1) HUP9900006A3 (hu)
IL (1) IL122923A0 (hu)
MX (1) MX9800411A (hu)
NO (1) NO980154L (hu)
PL (1) PL324527A1 (hu)
SK (1) SK3898A3 (hu)
WO (1) WO1997003985A1 (hu)
YU (1) YU42296A (hu)
ZA (1) ZA965934B (hu)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
CA2294480C (en) 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
EP1173167A4 (en) * 1999-04-30 2004-07-14 Lilly Icos Llc TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS
MXPA00003997A (es) * 1999-04-30 2002-03-08 Lilly Icos Llc Articulos de fabricacion.
AU4491200A (en) * 1999-08-03 2001-02-19 Lilly Icos Llc Beta-carboline pharmaceutical compositions
US20040152106A1 (en) * 1999-10-07 2004-08-05 Robertson Harold A. Gene necessary for striatal function, uses thereof, and compounds for modulating same
JP2003510349A (ja) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物
CN1378547A (zh) 1999-10-11 2002-11-06 辉瑞大药厂 用作磷酸二酯酶抑制剂的5－(2－取代的－5－杂环基磺酰基吡啶－3－基)－二氢吡唑并[4,3－d]嘧啶－7－酮类化合物
IL139456A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
DE60124085D1 (de) 2000-04-19 2006-12-07 Lilly Icos Llc Pde-v hemmer zur behandlung von morbus parkinson
WO2001078781A2 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
AU2001263278A1 (en) * 2000-06-23 2002-01-08 Lilly Icos Llc Cyclic gmp-specific phosphodiesterase inhibitors
CA2423357C (en) 2000-08-02 2008-05-27 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CN1264574C (zh) * 2000-09-06 2006-07-19 田边制药株式会社 口服制剂
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ES2248399T3 (es) 2000-10-02 2006-03-16 Lilly Icos Llc Derivados de piridoindol condensado.
EP1325007B1 (en) * 2000-10-02 2005-06-15 Lilly Icos LLC Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
WO2002036593A1 (en) * 2000-11-06 2002-05-10 Lilly Icos Llc Indole derivatives as pde5-inhibitors
DE60110124T2 (de) 2000-11-08 2005-12-01 Lilly Icos Llc, Wilmington Kondensierte pyrazindionderivate als pde inhibitoren
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
DE60219788T2 (de) * 2001-06-05 2008-01-17 Lilly Icos Llc, Wilmington Tetrazyklische verbindungen als pde5-inhibitoren
MXPA03011167A (es) 2001-06-21 2004-02-26 Lilly Icos Llc Derivados de carbolina utiles como ihibidores de pdev.
EP1442042A1 (en) * 2001-11-09 2004-08-04 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
US7335680B2 (en) * 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
JP2005536567A (ja) * 2002-07-31 2005-12-02 リリー アイコス リミテッド ライアビリティ カンパニー ピクテ−スペングラー反応の変法およびその産物
US20070010450A1 (en) * 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
WO2006049986A1 (en) * 2004-10-28 2006-05-11 Dr. Reddy's Laboratories Ltd. Polymorphic forms of tadalafil
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150297601A1 (en) 2012-10-05 2015-10-22 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN104804016B (zh) * 2014-01-23 2017-06-20 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
WO2019123285A1 (en) 2017-12-20 2019-06-27 Novartis Ag Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
US11098040B2 (en) * 2018-02-28 2021-08-24 Ferro Therapeutics, Inc. Compounds and methods of use
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GR79603B (hu) * 1982-07-24 1984-10-31 Pfizer
IT1217190B (it) * 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
EP0459666B1 (en) * 1990-05-31 1994-11-09 Pfizer Inc. Medicaments against impotence
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds

Also Published As

Publication number Publication date
EP0846118A1 (en) 1998-06-10
HUP9900006A2 (hu) 1999-04-28
ES2176471T3 (es) 2002-12-01
IL122923A0 (en) 1998-08-16
PL324527A1 (en) 1998-06-08
CN1195349A (zh) 1998-10-07
AU702324B2 (en) 1999-02-18
WO1997003985A1 (en) 1997-02-06
ATE216997T1 (de) 2002-05-15
ZA965934B (en) 1997-02-03
HRP960321B1 (en) 2003-06-30
GB9514465D0 (en) 1995-09-13
AU6419296A (en) 1997-02-18
JP4150818B2 (ja) 2008-09-17
DE69621026D1 (de) 2002-06-06
JPH11509535A (ja) 1999-08-24
MX9800411A (es) 1998-04-30
YU42296A (sh) 1998-12-23
NO980154L (no) 1998-03-10
CO4700455A1 (es) 1998-12-29
AR003455A1 (es) 1998-08-05
US5981527A (en) 1999-11-09
BR9609780A (pt) 1999-03-09
HRP960321A2 (en) 1998-08-31
CZ3298A3 (cs) 1998-06-17
CN1069318C (zh) 2001-08-08
SK3898A3 (en) 1998-11-04
CA2226761A1 (en) 1997-02-06
NO980154D0 (no) 1998-01-13
DE69621026T2 (de) 2002-08-22
EP0846118B1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
HUP9900006A3 (en) Cyclic gmp-specific phosphodiesterase inhibitors, their production and medicament containing them
HUP9600732A2 (en) Cyclic compounds containing nitrogen, their production and use as medicament
HUP9601529A3 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9901079A3 (en) 5- and 6-membered cyclic compounds containing nitrogenatom, pharmaceutical compositions containing them, their use for producing pharmaceutical compositions and their producing
HK1025096A1 (en) Disubstituted bicyclic heterocycles, their production and use as medicaments
HUP9602507A2 (en) Cyclic adhesion-inhibitors
HUP9802300A3 (en) N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9801201A3 (en) Taxoids, preparation thereof and pharmaceuticals containing same
BG98409A (en) 5-member heterocycles, method for their preparation and medicaments containing them
HUP9600549A3 (en) N-(3-benzofuranyl)urea-derivatives, medicaments containing the same and process for producing them
HU9502443D0 (en) Glycinamide derivatives, processes for their preparation and medicines containing them
HUP9600071A3 (en) Indolo-piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9603071A3 (en) Purin-6-one derivatives, producing and pharmaceuticals preparations containing them
NZ300778A (en) Quinoxalin-2-one, aza-quinoxalin-2-one and aza-quinolin-2-one derivatives and analogs; medicaments containing them
HUP9600876A3 (en) Benzonitril- and -fluoride derivatives, pharmaceutical compositions containing them, process for producing them and their use
NZ307950A (en) Cyclic amidines derivatives and medicaments thereof
HUP9802408A3 (en) Naphthyl and dihydronaphthyl-derivatives, and pharmaceutical compositions, containing them
HUP9901376A3 (en) 1-methylcarbapenem derivatives, their use, production thereof and medicaments containing the same
NZ307159A (en) Medicament containing tiagabine, antioxidant, and carrier
PL312693A1 (en) Oxathiolanes, method of their production and pharmaceutical compounds containing them
HUP9903715A3 (en) 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols, their use and medicaments containing them
HUP9600665A2 (en) Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
HUT73975A (en) Substituted benzol-sulfonyl-ureas and-thioureas, process for producing them, pharmaceutical compositions containing them and their use
HUT73982A (en) Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
HUP9800472A3 (en) New benzoxazinedion derivatives, process for producing them and pharmaceutical copositions containing them